MeiraGTx Holdings plc, a vertically integrated clinical-stage genetic medicines company, has delivered significant top-line growth in 2025, driven by its unique riboswitch gene regulation platform and expanding manufacturing footprint. Despite this revenue surge, the company continues to incur substantial net losses, underpinned by heavy R&D investment and ongoing operational costs. Its proprietary viral vector manufacturing facilities in London and Shannon underpin clinical and potential commercial supply, while strategic collaborations bolster its pipeline across diverse indications including xerostomia and Parkinson’s disease. Capital structure constraints and regulatory hurdles remain key challenges as MeiraGTx navigates scalability and commercialization milestones.